Autopsy report · NCT02138812
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Cause of deathFunding or business
“As another Mps1 inhibitor was being developed in parallel, the strategic decision was to move forward with the development of the follow up compound only.”
Life of this trial
- Ran for about 3 years 5 months before it stopped.
- 69 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Bayer
- Sponsor type
- Industry
- Conditions
- Medical Oncology
- Interventions
- BAY1161909; Paclitaxel
- Participants
- 69
- Sites
- 6
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.